TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06300307: Study of ATX-01 in Participants With DM1

Sponsor: ARTHEx Biotech S.L. · Phase: PHASE1/PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 56 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$2,144,975

Rescue Site Savings

+$1,400,800

Unlock Full NCT06300307 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06300307 Rescue Dossier →